Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mabwell (Shanghai) Bioscience Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
Nanjing Leads Biolabs Co.,Ltd
AstraZeneca
Genmab
Intergroupe Francophone de Cancerologie Thoracique
University Hospital, Lille
HC Biopharma Inc.
Bristol-Myers Squibb
PrECOG, LLC.
Shanghai Hengrui Pharmaceutical Co., Ltd.
CStone Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
Abramson Cancer Center at Penn Medicine
Qilu Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
BeiGene
Memorial Sloan Kettering Cancer Center
HRYZ Biotech Co.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
The Cleveland Clinic
Hyogo Medical University
Mayo Clinic
NRG Oncology
Canadian Cancer Trials Group
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Shandong Cancer Hospital and Institute
EMD Serono
Gilead Sciences
AstraZeneca
University of Chicago
Hansoh BioMedical R&D Company
Hansoh BioMedical R&D Company
Qilu Pharmaceutical Co., Ltd.
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
SUNHO(China)BioPharmaceutical CO., Ltd.
AstraZeneca
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Polaris Group
Merck Sharp & Dohme LLC
Refnot-Pharm Ltd
Shanghai Hengrui Pharmaceutical Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC